Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Gene & Protein in Disease|August 1, 2025
Exploring dopamine as the master regulator of brain circuitry and mental health genomeKenneth Blum, Eric R Braverman, Alireza Sharafshah, et al.
Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health|December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergiaKai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Acta Scientific Neurology|September 2, 2025
Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) ScreeningKai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Neurology (E-Cronicon)|December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)Kenneth Blum, Eric R Braverman, Milan Makale, et al.
Journal of Addiction Psychiatry|September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and PresentKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Research Square|December 3, 2025
Computational GWAS Meta Meta Analysis Revealing Cross Talk Between Cannabis CNR1 and DRD2 Receptors Optimizing Long-Term Outcomes for Cannabis Use Disorder (CUD) By Enhancing Dopamine Homeostasis Promoting High-Quality Cannabis MedicinalsKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Journal of Addiction Psychiatry|December 5, 2024
Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration TherapyFoojan Zeine, Nicole Jafari, David Baron, et al.
Pageof 2